Halozyme Therapeutics (HALO) Tops Q3 EPS by 5c; Offers FY23 Guidance

Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.75, $0.05 better than the analyst estimate of $0.70. Revenue for the quarter came in at $216 million versus the consensus estimate of $218.7 million.

GUIDANCE:

Halozyme Therapeutics sees FY2023 EPS of $2.70-$2.80, versus the consensus of $2.65. Halozyme Therapeutics sees FY2023 revenue of $825-845 million, versus the consensus of $836 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
• BRP Inc. (DOO) Reports Q2 Loss of Cd$0.18